|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
John H. Friedman of Easton Capital Investment Group Joins Sequella, Inc. Board of Directors
1/31/2011 9:13:30 AM
ROCKVILLE, Md.--(BUSINESS WIRE)--Sequella, Inc., a clinical-stage company focused on commercializing novel drugs for treatment of infectious diseases, announced today that John Friedman has joined its Board as an Independent Director. Mr. Friedman brings more than 30 years of venture investment experience to the Sequella Board. He is the Founding and Managing Partner of Easton Capital Investment Group. Prior to founding Easton Capital, he was a founder and Managing General Partner of Security Pacific Capital Investors, a $200-million private equity fund geared towards expansion financings and recapitalizations. Prior to joining Security Pacific, Mr. Friedman spent more than eight years at E.M. Warburg, Pincus & Co, where his last position was a Managing Director and Partner. Prior to Warburg Pincus, Mr. Friedman was an attorney with Sullivan and Cromwell.
|
|
|
|
|
|
|
|
|
|
|